中国药物警戒 ›› 2022, Vol. 19 ›› Issue (1): 87-90.
DOI: 10.19803/j.1672-8629.2022.01.19

• 安全与合理用药 • 上一篇    下一篇

头孢哌酮钠舒巴坦钠致缺血性脑血管病患者凝血功能异常的影响因素分析

梁河1, 蒙光义1, 钟丽球1, 周丽娟1, 庞家容2   

  1. 1玉林市第一人民医院药学部,广西 玉林 537000;
    2玉林市第一人民医院神经内科,广西 玉林 537000
  • 收稿日期:2020-02-25 出版日期:2022-01-15 发布日期:2022-01-20
  • 作者简介:梁河,女,本科,副主任药师,临床药学。
  • 基金资助:
    广西玉林市科学研究与技术开发计划项目（20171606）

Influencing factors of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium in patients with ischemic cerebrovascular disease

LIANG He1, MENG Guangyi1, ZHONG Liqiu1, ZHOU Lijuan1, PANG Jiarong2   

  1. 1Department of Pharmacy, First People's Hospital of Yulin, Yulin Guangxi 537000, China;
    2Department of Neurology, First People's Hospital of Yulin, Yulin Guangxi 537000, China
  • Received:2020-02-25 Online:2022-01-15 Published:2022-01-20

PDF (PC)

134

摘要： 目的 分析头孢哌酮钠舒巴坦钠致缺血性脑血管病患者凝血功能异常的影响因素。方法 对2015年1月1日至2019年9月30日我院102例应用头孢哌酮钠舒巴坦钠治疗的缺血性脑血管病患者临床资料进行回顾性分析。记录患者的一般资料、用药情况、肝肾功能、血清白蛋白含量、凝血功能,进行回归分析。结果 凝血功能异常发生率为42.16%（43/102）。Logistic回归分析结果表明,头孢哌酮钠舒巴坦钠应用天数、血肌酐、血清白蛋白为缺血性脑血管病患者发生凝血功能异常的独立危险因素（P<0.05）。结论 缺血性脑血管病患者合并肾功能不全、低蛋白血症可增加头孢哌酮钠舒巴坦钠致凝血功能异常的发生风险,头孢哌酮钠舒巴坦钠应用天数越长发生凝血功能异常的风险越大,临床应加强监测。

关键词: 头孢哌酮钠舒巴坦钠, 凝血功能异常, 影响因素, 缺血性脑血管病

Abstract: Objective To investigate the influencing factors of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium in patients with ischemic cerebrovascular disease. Methods The clinical data on 102 patients with ischemic cerebrovascular disease treated with cefoperazone sodium and sulbactam sodium in our hospital between January 1, 2015 and September 30, 2019 was retrospectively analyzed. The basic information, medications, liver and kidney function parameters, serum albumin levels and coagulation function parameters were recorded and analyzed using binary logistic regression analysis. Results The incidence of coagulation abnormalities was 42.16% (43/102). Logistic analysis showed that the number of days cefoperazone sodium and sulbactam sodium were used and serum levels of creatinine and albumin were independent risk factors for coagulation abnormalities in patients with ischemic cerebrovascular disease (P<0.05). Conclusion Ischemic cerebrovascular disease complicated with renal insufficiency and hypoalbuminemia could increase the risk of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium. The incidence of coagulation abnormalities increases with the number of days cefoperazone sodium and sulbactam sodium are used. Therefore, coagulation function should be monitored.

Key words: cefoperazone sodium and sulbactam sodium, coagulation abnormalities, influencing factors, ischemic cerebrovascular disease

中图分类号: